Trial · NCT02520141
Adverse events71
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 71
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Proteinuria | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 23 | 60 | |
| other | Thrombocytopenia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 13 | 60 | |
| other | Anemia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 11 | 60 | |
| other | Hyperbilirubinemia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 9 | 60 | |
| other | Alkaline phosphatase increase | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 9 | 60 | |
| other | AST increase | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 9 | 60 | |
| other | Hyponatremia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 9 | 60 | |
| other | ALT increase | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 8 | 60 | |
| other | Hyperkalemia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 7 | 60 | |
| other | Hypercalcemia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 5 | 60 | |
| other | Hypomagnesemia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 5 | 60 | |
| other | Creatinine | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 4 | 60 | |
| other | Hypoalbuminemia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 3 | 60 | |
| other | Hematuria | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 2 | 60 | |
| other | Hypermagnesemia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 2 | 60 | |
| other | Hypoglycemia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 2 | 60 | |
| other | Hypokalemia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 2 | 60 | |
| other | Prolonged PTT | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 1 | 60 | |
| other | Hyperglycemia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 1 | 60 | |
| other | Hypocalcemia | Investigations | Phase II Open-label, Single Arm Study of Ramucirumab Administered at 8 mg/kg IV. | 1 | 60 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02520141/events